EMEA MARKETING WITHDRAWAL
January 1st, 2003
BY KEITH NUTHALL
THE EUROPEAN Agency for the Evaluation of Medicinal Products (EMEA) has announced that the European Union marketing authorisation for hepatitis B treatment HEPACARE has been withdrawn by the European Commission. The decision followed manufacturer Celltech Pharmaceuticals Ltd's commercial decision to abandon plans to sell the medicine. Alternative vaccines are available in Europe.
THE EUROPEAN Agency for the Evaluation of Medicinal Products (EMEA) has announced that the European Union marketing authorisation for hepatitis B treatment HEPACARE has been withdrawn by the European Commission. The decision followed manufacturer Celltech Pharmaceuticals Ltd's commercial decision to abandon plans to sell the medicine. Alternative vaccines are available in Europe.
Full access to this article can be arranged with permission from the client that first ordered it. Please contact us to request access. Entries are uploaded to our archive at least one year after being published by a client – free access is restricted to International News Services journalists for background research only. The article date indicates when copy was filed to a client, not when posted to this archive. Upon client requests, International News Services will remove such articles from the archive or not upload them in the first place. They are included to demonstrate the breadth of topics undertaken by the agency and also to help promote clients’ coverage.